Cardiovascular Outcomes of Glp-1 Receptor Agonists and Sglt2 Inhibitors in Patients with Coronary Artery Disease: A Study with Emphasis on Overweight and Obesity

Abstract

Coronary artery disease often coexists with metabolic disorders, including overweight, obesity, and diabetes mellitus. This study describes cardiovascular outcomes among patients receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium glucose cotransporter-2 inhibitors (SGLT2 inhibitors), or conventional treatment, with particular attention to the burden of overweight and obesity. The clinical summary comprised 147 patients divided into GLP-1 RA (n=40), SGLT2 inhibitor (n=47), and conventional-treatment (n=60) groups, each with a reported 24-month follow-up. In the total cohort, 49 patients were overweight and 78 had obesity, together representing 86.4% of participants. Myocardial infarction occurred in 2, 3, and 5 patients, respectively; stroke in 1, 2, and 3; cardiovascular death in 1, 2, and 4; and hospitalization for heart failure in 2, 4, and 7. Diabetes mellitus was present in 40, 47, and 30 patients, respectively. Observed event proportions were numerically lower in the GLP-1 RA group than in the other groups, while unadjusted group comparisons did not establish statistically significant differences. The findings describe the observed cardiovascular event patterns in a clinical cohort with a substantial burden of excess body weight.